Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E6201 in Advanced Hematologic Malignancies
NCT02418000Phase 2Terminated
- Sponsor
- Spirita Oncology
- Start
- Apr 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of e6201 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Spirita Oncology. Started Apr 2015; status: terminated.
02
Drugs
e6201
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT02418000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418000.